Bonum Therapeutics, Inc.
Biotechnology · SEATTLE, WA
BiotechnologySEC Form D
Bonum Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on April 17, 2026, reporting $26,907,396 raised toward a $32,301,381 offering.
Incorporated in Delaware and based in SEATTLE, WA, it operates in the Biotechnology sector.
Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Bonum Therapeutics, Inc. has raised capital from private investors.
Browse more recently funded companies in Biotechnology.
Executives & Directors
- John MulliganExecutive Officer · Director · Promoter
- John McKearnDirector
- Monique SchiersingDirector
- Nicholas WalrodDirector
- Karl HandelsmanDirector
- Diane HollenbaughExecutive Officer
- Neela PatelExecutive Officer
- Mitchell MutzDirector
- Samuel BjorkDirector
- Gaurav AggarwalDirector
- Samuel BlackmanDirector
Recently funded in Biotechnology
Other companies that recently filed a Form D
$3.2MRaised
Goldenrod Therapeutics, Inc.
$10.0MRaised
Human Biotech, Inc.
$1.0MRaised
Optimeos Life Sciences, Inc.
$2.5MRaised
BioStem Technologies, Inc.
$10.0MRaised